Price T Rowe Associates Inc Alx Oncology Holdings Inc Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Alx Oncology Holdings Inc stock. As of the latest transaction made, Price T Rowe Associates Inc holds 10,622 shares of ALXO stock, worth $19,863. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,622
Previous 232,769
95.44%
Holding current value
$19,863
Previous $2.6 Million
97.5%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ALXO
# of Institutions
122Shares Held
40.7MCall Options Held
518KPut Options Held
142K-
Ven Bio Partners LLC San Francisco, CA9.7MShares$18.1 Million33.06% of portfolio
-
Vivo Capital, LLC Palo Alto, CA4.22MShares$7.89 Million3.76% of portfolio
-
Redmile Group, LLC San Francisco, CA4.04MShares$7.55 Million1.59% of portfolio
-
Vestal Point Capital, LP New York, NY3.6MShares$6.73 Million1.62% of portfolio
-
Black Rock Inc. New York, NY2.69MShares$5.03 Million0.0% of portfolio
About ALX ONCOLOGY HOLDINGS INC
- Ticker ALXO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,747,100
- Market Cap $76.2M
- Description
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...